Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and schistosomal infection in mice by Hessien, Mohamed H et al.
Hessien et al. BMC Gastroenterology 2010, 10:53
http://www.biomedcentral.com/1471-230X/10/53
Open Access RESEARCH ARTICLE
© 2010 Hessien et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Non-invasive index of liver fibrosis induced by 
alcohol, thioacetamide and schistosomal infection 
in mice
Mohamed H Hessien*1, Ismaiel M El-Sharkawi2, Ahmed A El-Barbary1, Doha M El-Beltagy1 and Ned Snyder3
Abstract
Background: Non invasive approaches will likely be increasing utilized to assess liver fibrosis. This work provides a new 
non invasive index to predict liver fibrosis induced in mice.
Methods: Fibrosis was generated by thioacetamide (TAA), chronic intake of ethanol, or infection with S. mansoni in 240 
mice. Both progression and regression of fibrosis (after treatment with silymarin and/or praziquantel) were monitored. 
The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and 
fibosis; (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index 
from the induced changes, and its prospective validation in a group of 70 mice.
Results: The index is composed of 4 serum variable including total proteins, γ-GT, bilirubin and reduced glutathione 
(GSH), measured in diseased, treated and normal mice. These parameters were highly correlated with both the 
histological stage and the grade. They were combined in a logarithmic formula, which non-invasively scores the 
severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced 
fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict 
the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values 
corresponding to histological stages 1, 2 and 3, respectively. Also, the index was correlated with stage and grade, (0.947 
and 0.859, respectively). The cut off values that cover the range between stages 0-1, 1-2 and 2-3 are 0.4, 1.12 and 1.79, 
respectively. The results in the validation group confirmed the accuracy of the test. The AUROC was 0.869 and there 
was good correlation with the stage of fibrosis and grade of inflammation.
Conclusion: The index fulfils the basic criteria of non-invasive marker of liver fibrosis since it is liver-specific, easy to 
implement, reliable, and inexpensive. It proved to be accurate in discriminating precirrhotic stages.
Background
The end stage complications of liver disease including
cirrhosis, and portal hypertension are related to advanced
fibrosis [1]. Management decisions in patients with
chronic liver diseases often depend upon the stage of liver
fibrosis. Hence, the accurate estimation of fibrosis is
important for the prevention of the subsequent complica-
tions. For 60 years, liver biopsy has been regarded as a
gold standard diagnostic method for assessing liver fibro-
sis. Despite its longstanding utility, liver biopsy has some
disadvantages which include its invasive nature [2],
expense, as well as inter observer variability. It also has
some negative features such as resistance of patients to
undergo liver biopsy due to the discomfort [3], possible
complications [2], and sampling error due to inadequate
liver specimen length or fragmentation [4,5]. Therefore,
alternative and accurate non invasive means to estimate
fibrosis are needed.
Multiple hepatic fibrosis markers utilizing either simple
blood tests or measurements of components of the extra-
cellular matrix (ECM) have been proposed, and some are
in clinical use. Imbert-Bismut and colleagues [6] pro-
posed an index combining 5 variables (bilirubin, gamma-
glutamyltranspeptidase (γ-GT), haptoglobin, alpha 2-
macroglobulin, and apoliprotein A1). The index ranges
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from 0-1 and currently is marketed as the FibroTest. Sub-
sequently, other hepatic fibrosis markers have been pro-
posed such as the Forns index [7], the AST/platelet ratio
index (APRI) [8], and the European or Enhanced Liver
Fibrosis Index [9]. These tests generally separate mild
from significant fibrosis or mild/moderate from advanced
fibrosis. Apart from Fibrotest, they usually have 2 cut offs
with an indeterminate zone, where the accuracy is less.
They can also be combined in decisional algorithms
[10,11]. Another non invasive tool is transient elastogra-
phy, either alone or combined with a hepatic fibrosis
marker such as the Fibrotest [11]. Other investigators
have suggested for best accuracy combining both a sim-
ple index and an ECM index [12,13]. Such approach
expands the number of investigations and increases the
cost required to stage the degree of fibrosis.
The majority of publications have been concerned with
fibrosis among HCV infected patients. Also, few studies
have monitored the regression of drug-mediated fibrosis.
This triggered our interest to establish a non-invasive
index to score the liver fibrosis in mice models induced
by injury from a hepatotoxin (thioacetamide, TAA),
chronic intake of alcohol or Schistosomal infection.
Moreover, we employed the index to monitor the revers-
ibility of fibrosis in mice treated with silymarin and/or
praziquantel (PZQ). The index includes four serum bio-
chemical markers (3 liver-specific and one oxidative
stress) combined in a logarithmic formula derived from
values of both tested and normal control mice.
Methods
Animal grouping
The study was carried out on 310 albino mice (MC1
strain), weighing 17.78-26.62 g, They were kept in breed-
i n g  c a g e s ,  a n d  t h e y  r e c e i v e d  s i m i l a r  b a s i c  c a r e  w i t h  a
standard diet. The test set included 240 mice, whereas the
validation set included 70 mice. Humane and ethical ani-
mal practices were followed that were under the standard
regulations dictated by the animal care committee of
School of Science, Tanta University.
1-Test groups
The test group of 240 mice was categorized into 12
groups (20 mice each): Group I included normal control
mice. Group II included mice intraperitonealy injected
with TAA. In group III mice were simultaneously treated
with both TAA and silymarin, whereas in group IV mice
were injected with TAA, for a month, then treated with
silymarin for a similar period. Group V mice were
infected with S. mansoni. In group VI, after being
infected with S. mansoni, mice were treated with PZQ.
Group VII mice were treated with silymarin for a month,
starting the day after infection with S. mansoni. In groups
VIII and IX, after being infected with S. mansoni, mice
were treated with silymarin or PZQ + silymarin, respec-
tively. Group X mice were given ethanol, whereas groups
XI and XII they were treated with silymarin during or
after ethanol intoxication, respectively. Figure 1 shows
the time, course of fibrogenesis, and treatments in differ-
ent groups.
2-Validation groups
70 mice were used to validate the proposed index (valida-
tion group). These animals were categorised into 4 sub-
groups. Three groups (20 mice each) were treated with
TAA, infected with S. mansoni or intoxicated with etha-
nol similar to groups I, V and X, respectively. Animals of
these groups were sequentially sacrificed, where 5-7 ani-
mals were killed every 10-15 days. The fourth group (10
mice) was untreated and used as a normal control group.
Induction and treatment of liver fibrosis
TAA-induced liver fibrosis was generated in mice by
intraperitoneal injection of 200 mg/Kg TAA (Sigma-
Aldrich Chemical Co., USA) twice a week for a month
[14]. S. mansoni-induced liver fibrosis was generated by
immersion of mouse tails into a suspension of 50 cercaria
for 30 minutes. Cercaria usually develop into larva, and
subsequently into an adult worm in about 42 days [15]. To
develop ethanol-induced liver fibrosis, ethanol (10%) was
Figure 1 Time course of exposure of mice to different liver fibrot-
ic inducers and treatments. Mice were categorized into 11 groups 
according to the fibrotic inducer with or without treatment, in addition 
to normal control group
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given to the mice in drinking water [16] for at least 35
days. Silymarin (Sedico Co., Egypt) was dissolved in
water (140 mg/dl) and taken orally [17]. As a reference
antischistosomiasis drug, mice (in groups VI and IX)
were orally injected by lavage with a single dose of 600
mg/Kg of mice body weight of PZQ (Biltricide, Epico Co.,
ARE). In the validation group (n = 70), liver fibrosis was
similarly induced like test groups, then animals were
given code numbers. Both the histological anlaysis and
the score value were independently caluculated for each
mouse.
Sampling
At the end of treatment period, animals were sacrificed,
where both blood and the liver tissues were collected.
Serum was recovered for biochemical investigations and
liver homogenate was prepared and used for determina-
tion of hepatic variables. In addition, a portion of the liver
was preserved in 10% formalin and used in histopatho-
logical analysis.
Biochemical markers
Serum total bilirubin, gamma glutamyltransferase (γ-GT)
(E.C.2.3.2.2.) activity, and total proteins (TP) were esti-
mated using the commercially available reagents follow-
ing the manufacturer instructions. Serum level of
reduced glutathione (GSH) was estimated according to
Ellman [18]. The method is based on the oxidation of
GSH by 5,5'-dithiobis-2-nitrobenzoic acid, [DTNB], and
the resultant yellow colored ion, is measured at 412 nm.
Liver homogenate (10%) was prepared and used to esti-
mate total malondialdehyde (MDA) according to Okhawa
and Ohishi [19]. The method depends on the reaction of
MDA with thiobarbituric acid (Sigma-Aldrich Chemical
Co., USA). Also, hydroxyproline (HP) content of collagen
was determined in liver according to Bergman and Lox-
lely [20] and Medugorac [21], where HP was hydrolyzed
with HCl, oxidized into pyrole and coupled with p-dime-
thyl-aminobenzaldehyde (Sigma-Aldrich Chemical Co.,
USA) forming a red color, which is measured at 558 nm.
The collagen content was calculated by multiplying the
HP concentration by 7.46, where this imino acid repre-
sents 13.4% of collagen. Tissue transglutaminase activity
was estimated in 100 μl liver homogenate, by a direct
spectrophotometric method developed by DeMacedo
and co-authors [22]. The method uses N,N-dimethyl-1,4-
phenylenediamine (DMPDA) (Sigma-Aldrich Chemical
Co., USA) as γ-glutamyl acceptor substrate and car-
bobenzyloxy L-glutamylglycine (Z-Gln-Gly) (Sigma-
Aldrich Chemical Co, USA) as a peptide γ-glutamyl
donor substrate. The resulting anilide, substituted with a
strong electron-donating group, is a chromophore that
absorbs light at 278 nm. Thus, the transamidation activity
of transglutaminase could be determined kinetically over
7 minutes period by measuring the increase in absor-
bance. A routine laboratory method was used in determi-
nation of proteins in liver homogenate assayed according
to Lowry et al., [23] using bovine serum albumin as a
standard.
Histological and non-invasive scoring of liver fibrosis
In order to analyze the histological features of liver
according to the METAVIR scoring system, the standard
protocol of tissue staining [24] was applied, where liver
tissues were fixed, paraffin-embedded and stained with at
least haematoxylin and eosin. Slides were examined by a
single pathologist unaware of animal treatments. Every
specimen was staged according to F0 to F4 system: F0 =
no fibrosis, F1 = portal fibrosis without septa, F2 = few
septa, F3 = numerous septa without cirrhosis, and F4 =
cirrhosis [25]. Histological activity (a measure of necroin-
flammatory lesions) was graded as follows: G0 = no histo-
logical activity, G1 = mild activity, G2 = moderate activity,
and G3 = severe activity.
Statistical analysis
Both serum and hepatic variables are expressed as a mean
(± standard deviation). The normal distribution of initial
data (bilirubin, TP, γ-GT and GSH) was tested by the Kol-
mogorov-Smirnov (KS) normality test. Accordingly, the
comparison between means were analyzed by the
ANOVA test. P values less than 0.05 were considered sig-
nificant. The correlation between index variables and the
histological stages and grades were investigated. Also, the
correlations between the non invasive score and the cor-
responding histological stage and grade were estimated
by the nonparametric Spearman correlation test. Com-
parisons between the histological stages of diffrent
groups were performed with Wilcoxon signed-rank test.
The Graphpad Instat software package (Graphpad, San
Diego, CA, USA) was used, however reciever operating
curves (ROC) and K mean clustring were performed by
SPSS-10.0 (strandard version, SPSS Inc.).
Results
Biochemical panel
To validate a non invasive model, we investigated two
panels of variables. The first "serum panel" included γ-
GT, bilirubin, TP, and GSH. Incorporation of ALT, AST
or ALP did not improve the model. The second "hepatic
panel" included MDA, HP and collagen. As table 1 shows,
the bilirubin has increased in mice treated with TAA,
alcohol or infected with S. mansoni (0.19 ± 0.017, 0.162 ±
0.017 and 0.127 ± 0.019 mg/dl, respectively) compared to
the mean level of normal mice (0.015 ± 0.006 mg/dl).
Treatment of animals with silymarin and/or PZQ, led to
variable degrees of reduction in bilirubin level. The best
improvement was achieved in mice treated with sily-Hessien et al. BMC Gastroenterology 2010, 10:53
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marin after cessation of intoxication (groups IV and XII)
and in mice dual-treated with silymarin and PZQ. Less
improvement has occurred in mice treated with the
drug(s) during the fibrogenesis process (gps III, VII and
XI). Also after treatment, γ-GT decreased to 10.4 ± 0.8,
9.7 ± 0.6 and 10.2 ± 0.97 U/L in groups IV, IX and XII,
respectively, similar to the normal control (9.27 ± 0.8 U/
L). The hypoproteineamia seen in mice with fibrosis (3.83
± 0.1, 4.74 ± 0.22 and 4.31 ± 0.2 g/dl) was significantly
improved after treatment. GSH levels revealed the devel-
opment of oxidative stress in mice with fibrosis (gps II, V
and X). Treatments of mice with silymarin and/or PZQ
after cessation of the fibrosis inducers restored the nor-
mal level of GSH, while 97.2%, 99.2% and 98.8% of the
normal GSH level was restored in groups IV, IX and XII,
respectively (Table 1).
In parallel, the increased hepatic MDA in fibrogenated
animals (Table 2) improved after silymarin treatment,
particularly in TAA and alcohol-induced fibrosis. In S.
mansoni infected mice, in contrast, neither silymarin nor
PZQ had a significant effect, where they minimally (11%
and 5%, respectively) decreased the MDA. The improve-
ment in both liver function and the oxidative stress con-
ditions significantly limited the overproduction of
hepatic collagen, which decreased to 122.14 ± 0.7, 118.88
± 9.76 and 119.21 ± 13.55, more or less similar to that of
healthy animals (110.80 ± 9.22). Hepatic MDA was nega-
tively correlated with serum GSH (r=-0.93) and both
Table 1: Levels of serum markers used to formulate the non-invasive fibrosis index
Fibrotic inducer Group No. (treatment) Bili-(mg/dl) γ GT (U/L) TP (g/dl) GSH (mM)
I (Normal) 0.015 ± 0.006 9.27 ± 0.83 6.10 ± 0.10 1.42 ± 0.04
TAA II (TAA) 0.19 ± 0.017a 28.49 ± 1.32a 3.83 ± 0.17a 0.82 ± 0.02a
III (TAA silymarin) 0.037 ± 0.006ab 13.9 ± 0.82ab 5.67 ± 0.22ab 1.34 ± 0.01ab
IV (TAA then Silymarin) 0.024 ± 0.009b 10.42 ± 0.82b 5.98 ± 0.13b 1.38 ± 0.03b
S. mansoni V (S. mansoni infection). 0.127 ± 0.019a 22.93 ± 0.52a 4.74 ± 0.22a 1.23 ± 0.02a
VI (PZQ after infection). 0.103 ± 0.019a 22.00 ± 0.63a 4.80 ± 0.23a 1.24 ± 0.03a
VII (Silymarin during 
infection).
0.054 ± 0.008ab 16.91 ± 1.04ab 5.25 ± 0.18ab 1.33 ± 0.03ab
VIII (Silymarin after 
infection).
0.065 ± 0.008ab 18.30 ± 0.97ab 5.07 ± 0.11ab 1.31 ± 0.01ab
IX (Silymarin after PZQ). 0.017 ± 0.006b 9.73 ± 0.63b 5.95 ± 0.15b 1.41 ± 0.02b
Ethanol X (Ethanol). 0.162 ± 0.017a 26.17 ± 1.32a 4.31 ± 0.20a 0.99 ± 0.03a
XI (Silymarin during 
ethanol intake).
0.028 ± 0.006ab 11.12 ± 1.04ab 5.85 ± 0.23ab 1.34 ± 0.01ab
XII (Silymarin after ethanol 
intake).
0.022 ± 0.008b 10.19 ± 0.97b 5.95 ± 0.35b 1.40 ± 0.02b
Bil: bilirubin, γ-GT: gamma glutamyltranseferase, TP: Total protein and GSH: reduced glutathione.
Small letters (a) and (b) indicate a significant change of the corresponding group compared to normal and untreated groups, respectively.Hessien et al. BMC Gastroenterology 2010, 10:53
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MDA and collagen were highly correlated with the non
invasive score (Table 3).
Modelling of hepatic fibrosis marker
Among the multiple biochemical variables studied in the
240 normal and fibrogenated animals in the test group,
the most useful were the bilirubin, total protein, γ-GT,
and GSH. This was indicated by the high correlation
between these markers and both histological stage and
grade (Table 4). Subsequently, a logarithmic empirical
formula was constructed:
Where: bil = serum total bilirubin, γ-GT = serum
gamma glutamyl transferase, TP = serum total protein
and GSH = reduced glutathione. Small letters (t and c),
refer to the "test" and "control" samples, respectively. To
calculate the non-invasive score, Bilc, γ-GTc, TPc and
GSHc were replaced with the corresponding levels mea-
sured in normal mice (0.015 mg/dl, 9.27 U/l, 6.1 g/dl and
log
Bilt GGTt TPc GSHc
Bilc GGTc TPt GSHt
⎫
⎬
⎭
=
⎧
⎨
⎪
⎩ ⎪
0
Table 3: Correlations between non-invasive score and hepatic markers (MDA and collagen)
Hepatic biochemical variables
Hepatic MDA Hepatic collagen
Non invasive score of training set 0.939, 0.000 0.901, 0.000
Table 2: Liver and oxidative stress markers in liver tissue
Inducer Group No. (treatment) HP Collagen MDA
I (Normal) 14.84 ± 1.24 110.80 ± 9.22 0.83 ± 0.02
TAA II (TAA) 42.65 ± 3.65a 318.19 ± 27.2a 2.15 ± 0.12a
III (TAA+ silymarin) 17.33 ± 1.97ab 129.24 ± 14.66ab 0.99 ± 0.07ab
IV (TAA then Silymarin) 16.14 ± 1.43b 122.14 ± 10.70b 0.87 ± 0.04 b
S. mansoni V (S. mansoni infection). 32.40 ± 2.35a 241.83 ± 17.50a 1.39 ± 0.14a
VI (Praziquantel after infection). 31.72 ± 2.68a 236.62 ± 20.02a 1.32 ± 0.05a
VII (Silymarin during infection). 19.28 ± 1.35ab 143.84 ± 10.08ab 1.09 ± 0.07a
VIII (Silymarin after infection). 21.92 ± 1.54ab 163.51 ± 11.47ab 1.14 ± 0.05a
IX (Silymarin after Prazaquantel). 15.94 ± 1.31b 118.88 ± 9.76b 0.85 ± 0.01b
Ethanol X (Ethanol). 37.96 ± 3.20a 283.19 ± 23.88a 1.74 ± 0.06a
XI (Silymarin during ethanol intake). 17.70 ± 1.58ab 132.04 ± 11.79ab 0.95 ± 0.02ab
XII (Silymarin after ethanol intake). 15.98 ± 1.82b 119.21 ± 13.55b 0.87 ± 0.03b
HP: hydroxyprolin, TP: total protein, MDA: malondialdehyde.
Small letters (a) and (b) indicate a significant changes of the corresponding group compared to normal and untreated groups, respectively.Hessien et al. BMC Gastroenterology 2010, 10:53
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1.42 mM), respectively. This formula, derived from test
set, was also used to assess fibrosis score of validation set.
Regression of fibrosis stage and inflammatory grade
In general, the histological analysis of treated animals
(Figure 2) revealed the regression of both the stage and
the grade of liver histology. Livers of untreated mice had
stages 3, 2 and 3. In TAA-induced fibrosis (gp II), the his-
tology revealed portoportal bridging, portal fibrosis,
piecemeal necrosis, fatty changes in hepatocytes, portal
inflammation and congested central veins. When sily-
marin was taken during the fibrogenesis stage (gp III), the
condition was improved with marked inflammatory reac-
tions in portal tracts, fatty changes in hepatocytes, and no
bridging in portal tracts. When the drug was taken after
cessation of TAA (gp IV), livers had enlarged hepatocytes
without structural changes, less inflammatory reactions
in portal tracts and less congestion in central vein. The
stage decreased from 3 to 1 (P < 0.05) in both cases. A
better regression pattern was observed in the groups
treated with alcohol, especially in group XII (gp X vs XI
or XII, P < 0.05). Slides of S. mansoni infected mice (gp V)
demonstrated the ova of S. mansoni surrounded by severe
inflammatory reaction (grade 3) and a congested central
vein. Treatment of mice with PZQ (gp VI) slightly
reduced the inflammatory reaction to (grade 2), however
it did not improve the stage (P > 0.05). More histological
improvement was obtained with dual treatment with
PZQ and silymarin (gp IX), whereas normal pattern (with
normal hepatocytes, few inflammatory reactions in por-
tal tract and no ova or adult worm) was seen in mice
treated with both drugs after cessation of S. mansoni
infection (Figure 3).
Biochemical scoring of fibrosis
After careful monitoring of the hepatic environment in
mice with liver fibrosis (with or without treatment), the
serum panel was utilized to formulate the fibrosis index
(Methods). The average score corresponding to the nor-
mal control mice in group 1 (with stage 0) was 0.127 ±
0.027 (range: 0-0.4). Liver specimens with histological
stage 1 had scored 0.668 ± 0.16 (ranges from 0.24 to 1.12).
Higher average scores were obtained in mice with stages
2 and 3 (1.35 ± 0.05 and 2.03 ± 0.13, respectively). The
center of each index range corresponding to each histo-
logical stage was determined by K-mean clustering (Table
5), where the mean values corresponding to healthy (F =
0), mild fibrosis (F = 1), moderate fibrosis (F = 2) and
s e v e r e  f i b r o s i s  ( F  =  3 )  w e re 0.11, 0.51, 1.11 and 1.85,
respectively. Also, the cut off values that cover the range
between stages 0-1, 1-2 and 2-3 were 0.4, 1.12 and 1.79,
respectively.
Biochemical versus histological scoring
The histological analysis of different groups matched the
score of the proposed index. Plotting receiver operating
characteristic curves (ROC) for index values versus cor-
responding histological stages (Figure 4) demonstrates
that the areas under the ROC curves (AUROC) were
0.954 (95% Confidence Interval 0.889-1.019), 0.979 (95%
Confidence Interval: 0.892-1.004) and 0.99 (95% Confi-
dence Interval: 0.0-1.0) for index values corresponding to
stages 1, 2 and 3, respectively) (Table 6). Within each cat-
egory the index was highly correlated with the corre-
sponding stage. In untreated and treated TAA, S.
mansoni and alcoholism groups the correlation between
the index and the histological stages were 0.98, 0.73 and
0.99, respectively.
Figure 2 Histological analysis of mice livers. TAA-induced liver fi-
brosis (A) was treated with silymarin during (B) or after (C) TAA. Also, al-
cohol-induced fibrosis (D) was treated with silymarin during (E) or after 
(F) alcohol intake. S. mansoni-induced fibrosis (G) was treated with 
praziquatel (H) or praziquantel then silymarin (I) after the development 
of schistosmiasis
gp. I: Normal control gp.II: TAA  Gp. III: Silymarin during TAA 
gp IV: Silymarin after TAA gp. V: S.mansoni infected mice. gp.VI: Praziquantel after 
Schistosomaisis
gp. VII: Silymarin during 
schistosomaisis  
gp. VIII: Silymarin after   
schistosomaisis 
gp IX: Prazaquantel and 
silymarin after chistosomaisis
gp X: Ethanol   gp XI: silymarin during ethanol .  gp XII: silymarin after ethanol 
Table 4: Correlations between the histological analysis 
(stage and grade) and each marker of the index panel
Non invasive serum variables Histology
Stage Grade
Bilirubin 0.922 0.894
γ-GT 0.942 0.893
T.Proteins -0.917 -0.856
GSH -0.898 -0.819Hessien et al. BMC Gastroenterology 2010, 10:53
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Validation group
To validate the index, three groups of mice were treated
with TAA, s. mansoni, or alcohol. Animals were sequen-
tially sacrificed, where a subgroup of mice was killed
every 10-15 days. The biochemical panel (bilirubin, γ-GT,
T proteins and GSH) (Figure 5 and Figure 6) was evalu-
ated and both the non- invasive score and the corre-
sponding histological analysis were carried out
independently. ROC curve was plotted. The area under
ROC curve was 0.869 (95% Confidence Interval: 0.790-
0.949) (Figure 4, panel D). Matching the obtained data
revealed a high correlation between the non invasive
score and both the stage and the grade, (0.947 and 0.859,
respectively) (Table 7).
Discussion
Without diminishing the importance of histological
assessment of liver fibrosis, non-invasive indices are mov-
ing towards accuracy and reliability. Previously proposed
panels have included 2 to 7 markers. Increasing the num-
ber of variables may improve the accuracy, however it
also increases the complexity and cost of the index. Previ-
ously reported indices included one (or more) variables
from four categories. These categories include: (i) ECM
proteins and enzymes involved in scar production, degra-
dation, or hepatic stellate cells (HSC) activation, such as
laminin, collagen, lysyl oxidase, prolyl hydroxylase, lysyl
hydroxylase hyalauronic acid, or tissue inhibitors of met-
Figure 4 Individual index values corresponding to different his-
tological stages in mice of validation group
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Figure 3 Regression of fibrosis monitored by histological analysis 
(Top) and by the non-invasive index (Bottom). The degree of fibro-
sis was evaluated by both the stage and inflammatory grade according 
to METAVIR system. (Stars): refers to significant changes between the 
corresponding groups versus group II, (Hearts) refers to significant 
changes between the corresponding groups versus group V, and 
(Black squires): refers to significant changes between the correspond-
ing groups versus group X. Also, 4 serum (non-invasive) markers were 
combined in a logarithmic formula and used to scale the degree of fi-
brosis in mice of different groups. The scale ranges from 0 (correspond-
ing to normal liver) up to 2 (corresponding to invasive fibrosis). The 
bottom panel presents the index values of different test groups
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Table 5: K-mean clustering and cut off values of the index corresponding to different precirrhotic histological stages
Score Histological stage
0123
Mean 0.127 ± 0.03 0.668 ± 0.29 1.350 ± 0.26 2.030 ± 0.13
K mean clustering 0.11 0.51 1.11 1.85
Cut-off 0.4 1.12 1.79Hessien et al. BMC Gastroenterology 2010, 10:53
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alloproteinases-1 (TIMP-1); (ii) Liver specific markers
(bilirubin, transaminases or globulin); (iii) Haematologi-
cal variables (platelets or PT); and (iv) Conjugated or
derived lipids (apolipoprotein and cholesterol).
This work adds one more predictive non-invasive index
that combines four simple, cheap and informative bio-
chemical serum variables. The panel consists of an aver-
age number of variables (four), including three liver-
specific, and one oxidative stress marker, simultaneously
assessed in both normal (hypothetical standard) and
tested samples. The aim was to formulate an index of
liver fibrosis, which is experimentally induced with three
different methods including: exposure to TAA, chronic
alcohol intake and, for the first time, infection with S.
mansoni, which predominantly exists in the Nile delta
and upper-Egypt. Because the study was performed on
mice, and due to the unavailability of animal model for
HBV or HCV infection, viral hepatitis-induced liver
fibrosis was not included. Also, the experiment was
designed to non-invasively score the fibrotic changes dur-
ing the compensated stages of fibrosis, where animals
were maintained in the precirrhotic stages (< F4) to mon-
itor the drug-mediated resolution of fibrosis.
Occupational TAA induced liver fibrosis in man is
quite uncommon compared to alcohol, viral and s. man-
Table 6: Area under receiver operating characteristic curves and range of confidence intervals for both test and validation 
sets
Animals Histological Stage AUROC Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
Training set 1 0.954 0.889 1.019
2 0.979 0.892 1.004
3 0.989 0.900 1.001
Validation set 0.869 0.790 0.949
Figure 5 Receiver operating curves (ROC) of the indices values 
corresponding to different histological stages. A, B and C represent 
the index values covering the range of stage 1 stage 2, and stage 3, re-
spectively where the AUROC and CI were 0.954, CI: 0.889-1.019; 
0.979,CI: 0.892-1.004 and 0.989, CI: 1.00-1.001 respectively. D: is the ROC 
of the indices values corresponding to different histological stages of 
validation group. AUROC is 0.869, CI: 0.790-0.949
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Figure 6 Serum (non-invasive) markers of validation set mea-
sured at 4 time points. The first time point (1) corresponds zero day 
of the normal untreated subset. For each mouse variables were com-
bined in a logarithmic formula and used to scale the degree of fibrosis 
in validation group. Bil: bilirubin, γ-GT: gamma glutamyltranseferase, 
TP: Total protein and GSH: reduced glutathione
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soni related chronic liver diseases. It is, however a potent
hepatotoxin that is rapidly eliminated and can cause
cumulative injury [26]. In addition to the oxidative stress
it generates, TAA decreases the level of some endogenous
antioxidants such as α-tocopherol [27]. Consequently, it
is anticipated that supplementation of mice with sily-
marin (a known anti-oxidant), will compensate the deple-
tion of the vitamin and challenge the oxidant effect of
TAA. Treatment of fibrosis in S. mansoni-infected mice,
in contrast, required a specific eradication of the parasite
with PZQ [28], followed by treatment with silymarin.
This pattern of progressive and regressive fibrogenesis
process was used to score the degree of scar formation (or
resolution) using a dual approach of histological and non-
invasive biochemical index.
The results revealed that oxidative stress commonly
developed in mice with liver fibrosis as indicated by the
depletion of serum GSH and elevated hepatic MDA. In
such conditions, HSCs are activated and excessively pro-
duce ECM proteins (2-fold increase of hepatic collagen
was observed). The over production of collagen was
accompanied with changes in liver markers and the cor-
r e s p o n d i n g  h i s t o l o g i c a l  s t a g e .  W e  b e l i e v e  t h a t  t h e
changes in the level (or the activity) of ECM proteins and
enzymes, reported in some previous indices [29], follows
the oxidative stress-mediated HSC activation. Novitskiy
and his co-workers [30] found that treatment of HSC
with ethanol led to the formation of ROS, activation of
HSC and subsequently promotion of fibrogenesis. Thus,
both GSH and hepatic MDA are able to monitor the ini-
tial steps rather than other ECM variables (collagens, HA,
and other ECM proteins). Also, due to the complexity of
ECM environment, inclusion of ECM variables may
decrease the sensitivity of the index. Moreover, ECM pro-
teins and enzymes are not exclusively liver-specific and
may reflect impaired hepatic clearance [31]. Mizushima
and co-workers [32], for instance, validated prolyl
hydroxylase and tissue inhibitor of metalloproteinase
(TIMP) as a marker of pancreatic fibrosis. Moreover,
ECM molecules are largely affected by the balance
between enzymes that control scar formation, stabiliza-
tion and degradation. In addition certain pathological
states, like pulmonary fibrosis, are associated with
increased levels of certain fibrosis markers [33]. Previ-
ously we found that transglutaminase (liver derived
enzyme known to stabilize the scar formation) did not
show significant differences among patients with differ-
ent grades of cirrhosis and HCC [34]. Also, the high cor-
relations (Spearman) we obtained between GSH with
both the histological stage and grade (-0.898 and -0.819,
respectively) have nominated GSH as an integral member
of the proposed index.
The remaining parameters included in the index are
known to be directly involved in cellular pathogenesis
and the synthetic capability of liver cells. ALT and AST
have repeatedly used in hepatic fibrosis indices (individu-
ally, as a ratio or combined with other variables such as
platelets [8,35,36]. ALT, in particular, was included in
some non-invasive panels to indicate the necro-inflam-
matory activity [37]. Detection of fibrosis in HCV
patients with normal transaminases [38] may decrease
their validity as fibrosis markers. Bilirubin and albumin
(the major fraction of plasma proteins) are traditionally
among the biochemical parameters used to monitor the
severity of liver disease. γ-GT is used as a marker of liver
damage by alcohol intake [32]. This enhanced our predic-
tive usefulness for the proposed index. The high correla-
tions between liver histology (stage and grade) from one
side and γ-GT (rather than ALT, AST, and ALP), bilirubin
and T. Proteins from the other side (Table 4), have
encouraged their combined involvement in the logarith-
mic formula. Liver dysfunction, leads to a decrease of the
level of two of the selected markers (GSH and TP) and an
increase the others (bilirubin and γ-GT). This predictive
pattern was formulated by the mutual reversing the test/
control ratio in the logarithmic formula.
Table 7: Correlations and Kruskal-Wallis test between non-invasive score and the liver histology of both training and 
validation sets
Histology
Stage Stage
Set Spearman 
Correlation
Kruskal-Wallis Spearman 
Correlation
Kruskal-Wallis
Non invasive 
Score
Training 0.947
P < 0.01
χ2 = 88.3
Sig 0.000
0.859
P < 0.05
χ2 = 82.4
Sig: 0.000
Validation 0.929
0.001
χ2 = 76.4
Sig: 0.000
0.890
P < 0.001
χ2 = 74.6
Sig: 0.000Hessien et al. BMC Gastroenterology 2010, 10:53
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The ground base is achieved in normal liver, where the
ratio will be (or near to) "1". Accordingly, the index starts
with "0", which corresponds to normal histological pat-
tern. The highest scores (2, 1.5 and 1.8) matched the his-
tological stages F3, F2 and F3 in groups II, V and X. A
marked decrease in fibrosis index was observed in treated
groups with index values ranging from 0.1 to 0.2.
Histologically, the highest fibrotic stage was observed
in mice in groups II, V and X (Figure 2). Different treat-
ments (with silymarin or PZQ), however, led to regres-
sion of the fibrotic stages to mild or moderate fibrosis in
TAA groups or complete resolution of fibrosis in schisto-
somiasis and alcohol-induced fibrosis. The index was
comparable to histological anaysis both following initial
treatments with alcohol, TAA, and s. mansoni as well as
following regression of fibrosis after treatment with sily-
marin and PZQ. High correlations were observed
between the score and both grade and stage. Also, the
values of AUROC inhances the potential usefulness of the
index (Figure 4 and Tables 6). Within groups the index is
correlated well with the corresponding histological
stages, where in TAA, S.mansoni and alcoholism groups
(r = 0.97, 0.84 and 0.97, respectively). Also, the data pro-
spectively obtained from the validation set enhances the
index reliability, where it matched the pathological stages
and grades, which were independently assessed.
This index resulted in higher AUROC values and better
i d e n t i f i c a t i o n  o f  i n d i v i d u a l  s t a g e s  o f  f i b r o s i s  t h a n  t h e
indices that are currently being used clinically in man.
This could partly be because compared with these indi-
ces, it was studied in a more controlled and predictable
environment over a shorter term. Nevertheless, its assess-
ment in chronic liver disease in man may be warranted.
Conclusion
This study assessed the fibrotic changes during the pro-
g r e s s i o n  a n d  r e g r e s s i o n  o f  f i b r o s i s .  I t  p r o v i d e s  a  n e w
experimental, reproducible and non invasive index of
liver fibrosis, formulated in a logarthmic formula, which
combined 3 common routine laboratory liver specific
markers in addition to GSH. The index can predict the
full range of precerrhotic stages and correlated well of the
histological staging and grading. Different etiologies
cause liver fibrosis in man including viral infection, s
mansoni, ethanol, and autoimmune diseases. This index
was utilized in mice experiments that assess the develop-
ment and/or treatment of fibrosis. It could be used in
future rodent models to assess damage and treatment for
various hepatic toxins and pathogens. If such a model
c o u l d  b e  v a l i d a t e d  i n  p r e d i c t i o n  o f  f i b r o s i s  i n  m a n ,  i t
would minimize the need for liver biopsy to assess
hepatic fibrosis.
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